Dubuque Bank & Trust Co. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 122,348 shares of the company’s stock after purchasing an additional 419 shares during the quarter. Johnson & Johnson accounts for approximately 2.6% of Dubuque Bank & Trust Co.’s investment portfolio, making the stock its 6th largest holding. Dubuque Bank & Trust Co.’s holdings in Johnson & Johnson were worth $16,905,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Dowling & Yahnke LLC lifted its holdings in Johnson & Johnson by 15.2% in the third quarter. Dowling & Yahnke LLC now owns 88,870 shares of the company’s stock valued at $12,279,000 after acquiring an additional 11,715 shares during the period. Chatham Capital Group Inc. lifted its holdings in Johnson & Johnson by 0.8% in the third quarter. Chatham Capital Group Inc. now owns 58,383 shares of the company’s stock valued at $8,067,000 after acquiring an additional 469 shares during the period. Ramsay Stattman Vela & Price Inc. lifted its holdings in Johnson & Johnson by 1.0% in the third quarter. Ramsay Stattman Vela & Price Inc. now owns 70,313 shares of the company’s stock valued at $9,715,000 after acquiring an additional 665 shares during the period. Oregon Public Employees Retirement Fund lifted its holdings in Johnson & Johnson by 0.7% in the third quarter. Oregon Public Employees Retirement Fund now owns 640,260 shares of the company’s stock valued at $88,465,000 after acquiring an additional 4,458 shares during the period. Finally, Stoneridge Investment Partners LLC lifted its holdings in Johnson & Johnson by 67.8% in the third quarter. Stoneridge Investment Partners LLC now owns 13,186 shares of the company’s stock valued at $1,822,000 after acquiring an additional 5,326 shares during the period. 66.20% of the stock is owned by hedge funds and other institutional investors.

Shares of JNJ stock opened at $132.40 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. The company has a market cap of $355.22 billion, a PE ratio of 16.19, a price-to-earnings-growth ratio of 2.11 and a beta of 0.68. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 22nd. The company reported $1.97 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.95 by $0.02. The business had revenue of $20.39 billion during the quarter, compared to the consensus estimate of $20.27 billion. Johnson & Johnson had a return on equity of 35.09% and a net margin of 18.75%. The business’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.74 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 8.57 earnings per share for the current fiscal year.

Johnson & Johnson announced that its Board of Directors has approved a stock buyback program on Monday, December 17th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to purchase up to 1.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 12th. Stockholders of record on Tuesday, February 26th will be paid a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 2.72%. The ex-dividend date is Monday, February 25th. Johnson & Johnson’s payout ratio is 44.01%.

In other Johnson & Johnson news, Director Charles Prince bought 2,000 shares of Johnson & Johnson stock in a transaction dated Friday, December 14th. The stock was acquired at an average cost of $134.37 per share, with a total value of $268,740.00. Following the purchase, the director now directly owns 28,520 shares in the company, valued at approximately $3,832,232.40. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CAO Ronald A. Kapusta sold 3,643 shares of the company’s stock in a transaction that occurred on Thursday, December 13th. The stock was sold at an average price of $147.31, for a total value of $536,650.33. Following the transaction, the chief accounting officer now directly owns 13,641 shares of the company’s stock, valued at $2,009,455.71. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 465,746 shares of company stock valued at $67,951,916. Corporate insiders own 0.22% of the company’s stock.

A number of research analysts have issued reports on JNJ shares. Citigroup decreased their price target on Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a report on Wednesday, January 2nd. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Tuesday, November 20th. Morgan Stanley set a $140.00 price target on Johnson & Johnson and gave the company a “hold” rating in a report on Thursday, December 20th. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Finally, Credit Suisse Group boosted their price target on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and an average target price of $142.20.

WARNING: This article was first posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2019/02/11/johnson-johnson-jnj-position-raised-by-dubuque-bank-trust-co.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Understanding Average Daily Trade Volume

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.